Personalised healthcare is key to a sustainable NHS

Insider Interview

Personalised healthcare is key to a sustainable NHS – and pharma can help

Doina Ionescu, General Manager at Merck, UK & Ireland, explores the importance of personalised healthcare and supported self-management, and highlights the work that Merck is doing in these areas

Pharmafocus: Why do you feel so passionately about personalised healthcare?

Doina Ionescu: To me, the optimisation of people’s individual treatment needs must be a priority, not a luxury. More personalised approaches to healthcare today are vital to achieve the best and most sustainable health management in the future. According to recent data, supported self-management can result in 19% fewer GP appointments and 38% fewer A&E attendances. There are clearly financial implications that are positive for the NHS budget. But it’s not only about cost savings – it’s also about enabling people to live better and healthier lives.

What is the current state of play?

The NHS Long-Term Plan outlines the aim that 2.5 million people are receiving personalised healthcare by 2024.

They concluded that personalised healthcare is critical in helping to reduce health inequalities, and support the future sustainability of our healthcare system.

COVID-19 put a break on personalised healthcare, but it has also accelerated the need for it, as prevention and proactive management of patients (and longer-term cost savings) will be more important post-COVID-19 than pre-COVID-19. While there is mounting evidence of the positive impact of personalised healthcare initiatives (particularly in mental health and learning disabilities) in primary care, personalised healthcare has not yet become systematically embedded in secondary care.

That’s why, at Merck, we want to focus on that issue, as well as the wider needs around personalised medicine and better/equitable genomic testing across the UK, so that newer, more targeted medicines reach the right patients.

What is Merck doing to further embed personalised healthcare specifically?

We have created a personalised healthcare framework of accountability, supported by a set of guiding principles that will be embedded within our businesses, and all future personalised healthcare activity we initiate, or support will be evaluated against them. The framework and the principles were based on insights collected from a multistakeholder survey, which was completed by over 100 individuals working within the NHS, pharma, patient organisations, and academia. We then took a deep dive into the survey findings with multidisciplinary experts, and explored how Merck could support the implementation of the personalised healthcare agenda, with a particular focus on shared decision making and supported selfmanagement.

How does the work Merck is doing in the UK & Ireland reflect the PHC Framework and Guiding Principles you have developed?

If we take multiple sclerosis (MS) as an example, we know that patient outcomes are better when patients have a key role to play in their ongoing treatment, and we believe this supports the NHS Recovery Plan post-COVID-19. And yet, depending on where patients live, their ability to be a part of their healthcare decisions will vary. MS patient numbers are only increasing, and services are already stretched. New models of care are needed. We want to support clinicians to make shared decision-making and supported self-management an embedded part of MS patient care, and we are working on some exciting plans to offer practical solutions and ideas for the sustainability of quality care for patients in supported self-management.

Merck also has a long-standing heritage in fertility, and we are about to launch a campaign to empower patients to become more informed, empowered, and play a more vocal role in their fertility treatment and care.

What needs to happen in the future?

What I found striking at the outset was that there seemed to be no clarity on which organisation would be accountable for ensuring that there is a systematic approach to planning and delivering services, particularly in secondary care. We shared our Framework and Guiding Principles with NHS leaders, and the response was really positive. There is an appreciation that pharma has a key role to play. Pharma has skills and capabilities such as R&D and access to big data, which can help to enhance health and close the gap in health inequalities. I think that we need a task force – just like the Vaccine Task Force – that has one consistent goal and that brings people together from industry, Integrated Care Systems (ICS), the NHS and patient organisations. Merck hopes to be able to play a pivotal role in driving additional initiatives forward in partnership with the NHS. The NHS can’t do it all by itself.

Doina Ionescu has been Merck’s General Manager for UK & Ireland since May 2020. Since joining Merck as a research scientist in 1998, she has held a diverse range of roles within the company including in Corporate Business Development, Corporate Mergers & Acquisitions and Commercial Operations. In June last year, she was elected to the Board of Directors for the Association of British Pharmaceutical Industry. She also represents Merck on the European Medicines Group, contributing towards the development of its policy positions and advocacy efforts. Doina is a physicist by background, and holds a Master’s degree in nuclear physics from the University of Bucharest, Romania, a PhD in physics from the University of Southampton, UK, and an Executive MBA from Ashridge Business School, UK.

To find out more, visit: www.merckgroup.com/uk-en/expertise/news.html

Alzheimer’s disease & age-related macular degeneration–how are they linked &what are the treatments?

Alexander Gebauer from Galimedix Therapeutics talks to Pharmafocus about the link between the two diseases and what the treatment landscape for both could look like in the future

What are biomolecular condensates, and will they be a breakthrough in diabetes treatment?

Ameet Nathwani at Dewpoint Therapeutics considers the current treatment landscape for both type 1 and type 2 diabetes, as well as evaluating the use of biomolecular condensates as a potential treatment option

The climate crisis: what is it and is pharma to blame?

Stefan Woxström at AstraZeneca Europe and Canada tells Pharmafocus about the link between climate change and human health, as well as considering how the pharma industry has contributed to the climate crisis

Improving Cardiovascular Disease Care And Awareness

Pharmafocus talks to Scott Curley about the risks of CVD and the imporance of getting the right treatment at the right time

Prostate Cancer In Europe: The Time To Act Is Now

Professor Henrik Van Poppel, member of the expert group for the Let's Talk Prostate Cancer initiative tells Pharmafocus about its new campaign

Alzheimer’s disease & age-related macular degeneration–how are they linked &what are the treatments?

What are biomolecular condensates, and will they be a breakthrough in diabetes treatment?

The climate crisis: what is it and is pharma to blame?

Improving Cardiovascular Disease Care And Awareness

Prostate Cancer In Europe: The Time To Act Is Now

Pharmafocus

Categories

Social Footprints